Gilead Sciences, Inc.

Biophausia Ab (Publ)

Kristofer Rubin

Carl-Henrik Heldin

Kristian Pietras

Arne Ostman

Arne &Ouml;stman

Rolf Reed

Mats Sjoquist

A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.

Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor

Method for treatment of tumors using nucleic acid ligands to PDGF

Primer compositions for anti-cancer agent delivery to solid tumors in mammals, including man, are disclosed. The primer comprise a pharmaceutically acceptable agent which increases the intracellular levels of cyclic adenosine monophosphate (cAMP) in the normal connective tissue cells within solid tumors. Such an agent may be selected from any agents which increase the intracellular levels of cAMP, e.g. agents binding to and stimulating receptors at the connective tissue cell surface within tumors, and agents inhibiting cAMP phosphodiesterase. Local administration of the primer to the solid tumor area results in a lowering of the interstitial pressure. Further, an agent delivery system and a method for delivery of anti-cancer agents to solid tumors are described.

Enhanced anti-cancer agent delivery to solid tumors by primer compounds

Growing community of inventors

Uppsala, Sweden

Kristofer Rubin